DROPLET MICROFLUIDICS-BASED SINGLE CELL SEQUENCING AND APPLICATIONS
20230049664 · 2023-02-16
Inventors
- Chuanyu LIU (Qiangdao, CN)
- Longqi LIU (Qiangdao, CN)
- Yaling HUANG (Qiangdao, CN)
- Yue YUAN (Qiangdao, CN)
- Mingyue WANG (Qiangdao, CN)
- Zifei WANG (Qiangdao, CN)
- Xiaoyu WEI (Qiangdao, CN)
- Ya LIU (Qiangdao, CN)
- Shanshan WANG (Qiangdao, CN)
- Chunqing WANG (Qiangdao, CN)
Cpc classification
C12N15/1065
CHEMISTRY; METALLURGY
C12Q2563/159
CHEMISTRY; METALLURGY
C12N15/1065
CHEMISTRY; METALLURGY
C12Q1/6806
CHEMISTRY; METALLURGY
C12Q2563/159
CHEMISTRY; METALLURGY
C12Q1/6806
CHEMISTRY; METALLURGY
International classification
C12N15/10
CHEMISTRY; METALLURGY
C12Q1/6806
CHEMISTRY; METALLURGY
Abstract
Provided are a sequencing library and applications thereof. The provided sequencing library includes a first nucleic acid molecule and a second nucleic acid molecule. The first nucleic acid molecule carries a cell index sequence and a droplet index sequence. The second nucleic acid molecule carries an insert fragment and a cell index sequence.
Claims
1. A droplet, comprising: a biological material containing a nucleic acid molecule; a droplet identification molecule carrying a droplet index sequence; and a first vector carrying a capture sequence and a cell index sequence, wherein the capture sequence is configured to capture at least one of the nucleic acid molecule and the droplet identification molecule.
2. The droplet according to claim 1, wherein the nucleic acid molecule is mRNA or DNA.
3. The droplet according to claim 1, wherein the biological material is in a form of cell, and wherein each droplet comprises one cell, and each droplet comprises at least one vector.
4. The droplet according to claim 1, wherein the droplet identification molecule further comprises a captured sequence, the captured sequence being connected to the droplet index sequence.
5. The droplet according to claim 1, further comprising a cell lysis reagent.
6. The droplet according to claim 1, wherein the droplet identification molecules are in a form of a long-chain molecule, the long-chain molecule comprising a plurality of droplet identification molecules in tandem, and wherein the plurality of droplet index sequences on the same long-chain molecule has an identical nucleic acid sequence.
7. The droplet according to claim 6, wherein the long-chain molecule further comprises an endonuclease recognition sequence located between two adjacent droplet identification molecules of the plurality of droplet identification molecules, and wherein the droplet further comprises an endonuclease configured to cleave the endonuclease recognition sequence.
8. The droplet according to claim 7, wherein the endonuclease recognition sequence is a double-stranded sequence, and the droplet identification molecule is a single-stranded sequence.
9. The droplet according to claim 1, wherein the droplet identification molecule is in a form of a second vector, the second vector carrying a plurality of droplet identification molecules.
10. The droplet according to claim 9, wherein the plurality of droplet identification molecules is connected to the second vector through a covalent bond or any other connection manner, and wherein the plurality of droplet identification molecules each further comprises a captured sequence, the captured sequence being connected to the droplet index sequence.
11. The droplet according to claim 10, wherein the covalent bond is a disulfide bond.
12. The droplet according to claim 10, further comprising: a cleavage reagent capable of cleaving a connection between the plurality of droplet identification molecules and the second vector.
13. The droplet according to claim 12, wherein the cleavage reagent is DTT.
14. The droplet according to claim 1, having a water-in-oil structure.
15. The droplet according to claim 1, wherein the droplet identification molecule is a long linear nucleic acid molecule, the long linear nucleic acid molecule comprising: a 5′-end sequence and a 3′-end sequence; a replication-initiating sequence; a captured sequence; and the droplet index sequence, wherein the 5′-end sequence and the 3′-end sequence constitute an endonuclease recognition sequence.
16. A method for analyzing single-cell nucleic acid, comprising: providing a single-cell suspension containing dispersed single cells, and mixing the single-cell suspension with droplet identification molecules to obtain a cell suspension, each of the droplet identification molecules carrying a droplet index sequence; placing the cell suspension, a first vector, and an oil at different positions of a microfluidic chip in such a manner that the cell suspension, the first vectors, and the oil pass through a same channel to obtain the droplet according to claim 1; performing demulsification and library construction on the droplet to obtain a sequencing library; and sequencing and analyzing the sequencing library to obtain nucleic acid information of the single cell.
17. The method according to claim 16, wherein: a concentration of the single-cell suspension ranges from 100 to 200 cells per microliter; a concentration of the droplet identification molecules ranges from 105 to 108 copies per microliter; and a concentration of the first vectors ranges from 2,000 to 3,000 per microliter.
18. A sequencing library constructed by using the droplet according to claim 1, the sequencing library comprising: a first nucleic acid molecule carrying the cell index sequence and the droplet index sequence; and a second nucleic acid molecule carrying an insert fragment and the cell index sequence.
19. The sequencing library according to claim 18, wherein the second nucleic acid molecule further comprises a Unique Molecular Identifier, and wherein the Unique Molecular Identifier has a length ranging from 6 nt to 15 nt.
20. The sequencing library according to claim 18, wherein the cell index sequence has a length ranging from 10 nt to 16 nt, and wherein the droplet index sequence has a length ranging from 6 nt to 15 nt.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0058] The above and/or additional aspects and advantages of the present disclosure will become apparent and readily understood from the following description of embodiments taken in conjunction with the accompanying drawings, in which:
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
DESCRIPTION OF EMBODIMENTS
[0079] The embodiments of the present disclosure are described in detail below, and examples of the embodiments are illustrated in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are illustrative and are intended to explain the present disclosure, and they should not be construed as limiting the present disclosure.
[0080] In the description of the present disclosure, the relevant terms herein are explained and illustrated, and these explanations and illustrations are only for the convenience of understanding the solutions, and should not be regarded as a limitation on the claimed solutions of the present disclosure.
[0081] Herein, a nucleic acid molecule may refer to an RNA molecule, a DNA molecule, or a modified DNA molecule and/or RNA molecule, or an unmodified DNA molecule and/or RNA molecule. Those skilled in the art can specifically determine, based on the context, whether it is an RNA molecule, or a DNA molecule, or both an RNA molecule and a DNA molecule. In addition, the connection of nucleic acid molecules, unless otherwise specified, refers to one of the most common connection through a 3-5′ phosphodiester bond. Unless otherwise specified, when these different nucleic acid molecules are connected, it is not required that the nucleic acid molecules are connected directly, and they may be connected through other nucleic acid molecules, as long as they are on the same nucleic acid chain or on the same ring.
[0082] Herein, “cell index sequence”, “droplet index sequence” or “captured sequence”, etc., is a fragment of nucleic acid molecule. As mentioned above, these nucleic acid molecules may be RNA or DNA molecules. The different expressions are only intended to indicate the different functions of these nucleic acid sequences. Those skilled in the art can understand the effects of the sequences represented by the various expressions according to the context.
[0083] For example, herein, the cell index sequence (cell barcode) can be used to indicate that the sequencing reads are from the same cell. The droplet index sequence (droplet barcode) can indicate that the sequencing reads are from one droplet. The capture sequence refers to a sequence used to pair with and thus capture other nucleic acid molecules. The captured sequence refers to a sequence capable recognizing the capture sequence, and usually, the captured sequence is reverse complementary with the capture sequence to capture nucleic acid molecules.
[0084] It is required to input a large input amount of cells when performing single-cell library construction and sequencing based on a droplet microfluidic platform. In order to solve such a problem, in the present disclosure, a plurality of microbeads can be encapsulated in one droplet during the preparation of droplets, and sequencing reads in these microbeads from one droplet are then determined to improve the utilization of cells.
[0085] According to an embodiment of the present disclosure, the droplet may contain a biological material, a droplet identification molecule, and a first vector. The biological material contains the nucleic acid molecules. The droplet identification molecule carries a droplet index sequence. The first vector carries a capture sequence and a cell index sequence. The capture sequence is configured to capture at least one of the nucleic acid molecule and the droplet identification molecule. The first vector may further carry an amplification recognition sequence.
[0086] According to an embodiment of the present disclosure, the droplet identification molecule in the droplet can be obtained by means of DNB technology, as illustrated in
[0087] The droplet identification molecule obtained by means of DNB technology is provided in the form of single strand, but the endonucleases recognize a double-stranded nucleic acid molecule. In this regard, the oligo-stranded nucleotide capable of anchoring to the endonuclease recognition sequence can then be hybridized with the above endonuclease recognition sequence, which is convenient for subsequent digestion with the endonuclease, thereby obtaining a large number of identical droplet identification molecules.
[0088] In addition, the DNA nanoball and the biological material can be pre-mixed, the vector and the endonuclease can be pre-mixed, and then droplet encapsulation can be performed using a conventional droplet microfluidic platform. The DNA nanoball is fragmented into small fragments under the action of restriction endonuclease. The small fragments are captured by the vectors (such as microbeads) with polyT, and the vectors from one droplet will capture the same droplet index sequences. As illustrated in
[0089] According to an embodiment of the present disclosure, the concentration of DNA nanoballs is 10.sup.5 to 10.sup.8 copies per microliter in such a manner that a single droplet contains at least one DNA nanoball. Under this concentration condition, most of the single droplets contain one DNA nanoball; and a few of the single droplets contain two or more DNA nanoballs. In this case, multiple magnetic beads present in one droplet can capture two types of droplet index sequences, and multiple magnetic beads present in other droplets can capture other droplet index sequences. In combination with the correlation between encapsulation of multiple nanoballs and capture of multiple magnetic beads in the droplet, it is possible to calculate which magnetic beads are from one droplet.
[0090] According to an embodiment of the present disclosure, the droplet identification molecule in the droplet may be provided in a form of a vector, which is referred to as a second vector in order to be distinguished from the first vector carrying the cell index sequence. That is, the droplet identification molecule may be provided in the form of the second vector, and the second vector carries a plurality of droplet identification molecules. Each of the plurality of droplet identification molecules may be connected to the second vector by a covalent bond or other means. Each droplet identification molecule, in addition to carrying the droplet index sequence, may further contain the captured sequence, and the molecule captured sequence is connected to the droplet index sequence. The droplet identification molecule can be connected to the vector through a covalent bond, for example, a disulfide bond. Thus, some covalent bond cleavage reagents, such as DTT, may be subsequently used to break the covalent bond and release the droplet identification molecule, thereby facilitating capture by the capture sequence carried on the first vector. Alternatively, the second vector can be a hydrogel microparticle, and the plurality of droplet identification molecules can be embedded in the hydrogel microparticle, and the hydrogel can be melted under suitable reaction conditions to release the droplet identification molecules.
[0091] According to an embodiment of the present disclosure, generally speaking, the applicant second vector may be a magnetic bead, and the size of the magnetic bead may generally be smaller than that of the first vector. The second vector carries a plurality of identical droplet index sequences. When droplets are formed subsequently, the covalent bond cleavage reagent in the droplet can destroy the covalent connections between the droplet index sequences and the second vector, without affecting the hydrogen bond connections between nucleic acid molecules, thereby releasing a large number of droplet index sequences in the droplet. The large number of droplet index sequences released can be captured by the first vector, and thus the vectors from one droplet will capture the same droplet index sequences. As illustrated in
[0092] Then, the conventional droplet microfluidic technology is used to perform demulsification, followed by reverse transcription reaction, enzyme digestion of empty oligonucleotides on the surface of the vector, cDNA amplification, library construction, sequencing and analysis, thereby completing single-cell sequencing.
[0093] The solutions of the present disclosure will be explained below in conjunction with examples. Those skilled in the art can understand that the following examples are only used to illustrate the present disclosure, but they should not be construed as limiting the scope of the present disclosure. The specific technique or condition indicated in the examples shall be that described in the literature in the related art or in the specification of used product, unless specifically indicated. The reagents or instruments used without indication of the manufacturers are the conventional products that can be purchased.
Example 1
[0094] Example 1 provides a method for preparing a sequencing library and performing high-throughput sequencing. The provided method is implemented through several steps, including: DNA nanoball preparation, single cell suspension preparation, microbead preparation, droplet generation, demulsification, reverse transcription RT reaction, enzyme digestion, cDNA amplification, fragmentase library construction, high-throughput sequencing, etc.
[0095] 1. Preparation of DNA Nanoballs
[0096] Referring to
[0097] 1.1 Primer Sequence Synthesis
[0098] Artificial synthesis of the following sequence:
[0099] DNB oligo sequence:
TABLE-US-00001 5′-Pho-CTAATA TTTTTTTTTTT TTTTTTTTTTTVAACATGA
GCTA AAGTCGGAGGCCAAGCGGTCTTAGGAAGACAA
GGTCT-3′
[0100] Explanation: UMI digestion site separated and located at two ends of the sequence (which will be connected after cyclization)+a number of protecting bases for restriction digestion at the two ends of the digestion site+PolyT sequence (forming PolyA sequence after forming the DNB)+fixed sequence+DNB UMI+PCR adapter sequence (because it cannot be interrupted for library construction, the adapter can be identified and amplified during Sample index amplification).
[0101] Specifically, “CTAATA” and “GGTCT” shown in bold with single underline in the above sequence represent the digestion site of BsaI restriction endonuclease, which is separated and located the two ends of the sequence (to be connected with each other after cyclization). “ATACAATA” and “AGATA” denoted with the dotted line in the above sequence are protecting bases for restriction digestion, and for improving the efficiency of restriction digestion. In the above sequence, “TTTTTTTTTTTTTTTTTTTTTV” is synthesized into the PolyA sequence after making DNB, and the PolyA sequence can be complementary to and thus be captured by the oligonucleotide sequence on the magnetic bead. The 10 nt bases “N” in the sequence represent a random sequence for labeling the droplet (i.e., the droplet index sequence as mentioned above), and each DNB carries a different index sequence. The “AAGTCGGAGGCCAAGCGGTCTTAGGAAGACAA” denoted with double-underline in the above sequence is a PCR adapter, which is complementary to the library adapter PCR primer for amplification during library construction.
[0102] Splint oligo: 5′-GTATTATTAGAGACCTATCT-3′. The Splint oligo is a cyclization complementary primer.
[0103] Digestion site complementary sequence (Digestion site complementary oligo):
TABLE-US-00002 5′-AGATAGGTCTCTAATAATACA-3′
[0104] Explanation: 5′-end and 3′-end of the synthesized DNB-oligo sequence contain the digestion site sequences to be cyclized and spliced together to form a complete digestion site, thereby forming a DNB-oligo ring. Then, the formed DNB-oligo ring is used for rolling circle replication and amplification to form DNBs, the synthesized single strand is a complementary strand of the DNB-oligo ring, and then the complementary sequence of the digestion site is added. Therefore, the complementary sequence is consistent with the sequences at the two ends of the original oligo.
[0105] 1.2 Single-Stranded DNB Oligo Cyclization
[0106] a. 200 to 400 ng of DNB oligo sequences was placed into a new 0.2 ml PCR tube and the tube was added with TE Buffer (Cat. No. AM9849) to a total volume of 47 μl.
[0107] b. 3.0 μl of 20 μM Splint oligo was added, mixed and centrifuged briefly to precipitate to the bottom of the tube.
[0108] c. The tube was placed in a PCR amplifier and incubated at 95° C. for 3 minutes.
[0109] d. Immediately after the reaction, the PCR tube was transferred to ice and stood for 5 minutes.
[0110] e. A single-strand cyclization reaction solution was prepared on ice: 3.2 μl of TE Buffer, 6 μl of 10×TA buffer (Cat. No. Y038), 0.6 μl of 100 mM ATP (Cat. No. R1441), and 0.2 μl of 600 U/μl T4 DNA Ligase (Cat. No.: BGE004).
[0111] f. 10 μl of the prepared single-strand cyclization reaction solution was pipetted into the above PCR tube, mixed by vortex, and centrifuged briefly to precipitate the reaction solution to the bottom of the tube.
[0112] g. The PCR tube was placed on the PCR amplifier, incubated at 37° C. for 30 minutes, and thermally covered at 75° C.
[0113] h. A digestion reaction solution was prepared on ice: 1.0 μl of TE Buffer, 0.4 μl of 10×TA buffer, 1.95 μl of 20 U/μl EXO I (Cat. No. 01E00MS), and 0.65 μl of 100 U/μl EXO III (Cat. No. 01E011HS).
[0114] i. 4 μl of the digestion reaction solution was pipetted into the single-stand cyclization product, mixed by vortex, and centrifuged briefly to precipitate the reaction solution to the bottom of the tube.
[0115] j. The tube was placed in the PCR amplifier, incubated at 37° C. for 30 minutes, and thermally covered at 75° C. The single-stranded oligonucleotide strands, which were not cyclized, were digested and degraded by the digestion reaction solution.
[0116] k. After completion of the reaction, 3 μl of 0.5M EDTA (Cat. No.: AM9260) was added, mixed well and centrifuged.
[0117] l. 90 μl of PEG32 (Cat. No.: Y041) magnetic beads was used to recover the above digestion products, 32 μl of TE Buffer was used to elute the DNAs, and the concentration of single-stranded product was detected with Qubit® ssDNA Assay Kit (Cat. No.: Q10212).
[0118] 1.3 RCA and digestion site hybridization reaction
[0119] a. The following reaction system was prepared with make DNB kit (Cat. No. 1000012552) on ice: 4 μl of single-stranded product ssDNA (10 ng), 4 μl of 10× Phi29 Buffer, 1.0 μl of 20 μM Splint oligo, 16 μl of TE Buffer, and 15 μl of H.sub.2O.
[0120] b. 40 μl of the above reaction mixture was evenly mixed with a vortex shaker and centrifuged in a mini centrifuge for 5 s.
[0121] c. The tube was placed in the PCR amplifier, incubated 95° C. for 1 min, 65° C. for 1 min, and 40° C. for 1 min, the thermal cover at 105° C.
[0122] d. DNB polymerase mixture solution II (LC) was taken, centrifuged briefly for 5 s, and stored in an ice box for later use.
[0123] e. After completion of the reaction in step c, the PCR tube was taken out and added with 40 μl of make DNB enzyme Mix and 4 μl of make DNB enzyme Mix II to the tubes while being placed on ice.
[0124] f. The mixture was evenly mixed with a vortex shaker, and centrifuged for 5 s in a mini centrifuge.
[0125] g. The tube was placed in the PCR amplifier, incubated at 30° C. for 20 minutes, the task was terminated immediately when the temperature dropped to 4° C.; the PCR tube was transferred to the ice box, added with 20 μl of DNB stop buffer, and slowly mixed 5-8 times with a flaring pipette, without shaking or centrifuging.
[0126] h. The DNB concentration was measured using the Qubit® ssDNA Assay Kit.
[0127] i. 20 μl of the above reaction product, DNBs, was added into a new PCR tube, and 10 μl of 10 μM Digestion site complementary oligo, 10 μl of 10× Cutsmart buffer (Cat. No.: B7204S), and 60 μl of H.sub.2O were added and gently pipetted 5-8 times, without shaking and centrifuging.
[0128] j. The tube was placed in the PCR amplifier, incubated at 55° C. for 2 minutes, 40° C. for 2 minutes, 30° C. for 2 minutes, 20° C. for 2 minutes, 10° C. for 2 minutes, and 4° C. for 2 minutes.
[0129] Explanation: this process is the annealing binding of primers complementary to the digestion sites. Generally, the complementary primers on the DNB are at 55° C. during sequencing by the sequencer, and thus 55° C. gradient annealing strategy was adopted.
[0130] k. 10 μl of the above product was added into a new PCR tube, and 90 μl of EB buffer was added for quantitative dilution, and the mixture was placed on ice for later use.
[0131] 2. Preparation of Single Cell Suspension
[0132] 2.1 Single cell suspensions for 293T cell line and NIH3T3 cell line were prepared by trypsin digestion, washed with PBS (Cat. No.: 10010031) (containing 0.04% BSA) 1-2 times, and filtrated with 40 μm cell sieve.
[0133] 2.2 The cell concentration was detected with a cell counting plate or counter.
[0134] 2.3 Based on the cell concentration, 20,000 cells were taken through pipette each time, and the cell pellet was collected after centrifugation at 300-500 g, and 100 μl of Cell Resuspension Buffer was added to resuspend the cells.
[0135] 2.4 Before loading the sample, 10 μl of the DNB product obtained in step k was added in the above step 1.3 to the Cell Resuspension Buffer, mixed evenly with a flaring pipette tip, and placed on ice for later sample loading.
[0136] 3. Preparation of Microbeads
[0137] 3. Microbead Preparation
[0138] 3.1 With reference to the article published by BGI about stLFR magnetic bead preparation method (Efficient and unique co-barcoding of second-generation sequencing reads from long DNA molecules enabling cost effective and accurate sequencing, haplotyping, and de novo assembly, https://genome.cshlp.org/content/early/2019/04/02/gr.245126.118), magnetic beads (purchased from Spherotech, USA, Cat. No.: SVM-200-4, https://www.spherotech.com/coa_mag_par.htm) were subjected to surface oligonucleotide coating to obtain magnetic beads with oligonucleotides on the surface. 200 μl of the magnetic beads (220,000) were pipetted and added into 0.2 ml PCR tube, placed on a magnetic stand for 2 min, and the supernatant was removed.
[0139] 3.2 The PCR tube was removed from the magnetic stand, and added with 200 μl of 1× Buffer D (1 mM EDTA, 9 mg/ml 85% KOH) to suspend the magnetic beads.
[0140] 3.3 The tube was incubated at room temperature for 5 min.
[0141] 3.4 The tube was placed on the magnetic stand for 2 min, and the supernatant was removed.
[0142] 3.5 The PCR tube was kept on the magnetic stand, added with 200 μl of 1× Buffer D, stood for 30 s, and the supernatant was removed.
[0143] 3.6 200 μl of LSWB was added and stood for 30 s, and then the supernatant was removed.
[0144] 3.7 The previous step repeated.
[0145] 3.8 200 μl of Lysis Buffer (6% Ficoll PM-400 (Cat. No.: 17-0300-10), 0.2% Sarkosyl (Cat. No.: L7414), 20 mM EDTA, 200 mM Tris pH 7.5 (Cat. No.: T2944-1L), H.sub.2O) was added and stood for 30 s, and then the supernatant was removed. The PCR tube was removed from the magnetic stand, added with 100 μl of Lysis Buffer and 5.5 μl of 1M DTT, and finally added with 4.5 μl of BsaI (Cat. No.: R0535S) restriction endonuclease. The magnetic beads were suspended with a low adsorption pipette tip on ice.
[0146] 4. Droplet Generation
[0147] 4.1 A protective film on a surface of a chip was teared off, and the chip was placed in a chip slot region of a droplet generator. The chip has a structure as illustrated in
[0148] 4.2 An A-end of a connection tube on a collection cap (contacting the connection tube at the bottom of the collection tube) was placed into an outlet hole of the chip.
[0149] 4.3 A 50 ml syringe was placed on a fixing holder and the push rod was pushed to an initial position. A blunt-end syringe needle was used to connect the syringe with the B-end of the connecting tube on the cap of the collection tube (without contacting the connecting tube at the bottom of the collection tube).
[0150] 4.4 200 μl of droplet generation oil was added to the collection tube, the collection cap was tightened, and the collection tube was placed upright on the fixing holder.
[0151] 4.5 The cells were evenly mixed through gentle pipetting, and 100 μl of the single cell suspension (obtained in step 2 above) was added to the cell well of the chip, under the premise that the pipette tip touched the bottom of the well.
[0152] 4.6 The magnetic beads were evenly mixed through gentle pipetting, and 100 μl of magnetic beads (obtained in step 3 above) were added to the bead well of the chip, under the premise that the pipette tip touched the bottom of the well.
[0153] 4.7 350 μl of the droplet generation oil was immediately added to the oil well of the chip.
[0154] 4.8 The push rod of the syringe was quickly pulled to the slot position, and the push rod was clamped at the slot.
[0155] 4.9 A timer was activated for 8 min and the droplets were collected.
[0156] 4.10 After 8 minutes, the collection cap on the collection tube was immediately unscrewed. The connection tube of the outlet hole of the chip was pulled out, and the connection tube was stretched vertically. The droplets in the tube flow into the collection tube, and then an ordinary collection tube cap was used for replacement.
[0157] 4.11 The collection tube stood still at room temperature for 20 min to fully bind mRNA molecules to the magnetic beads.
[0158] 5. Demulsification
[0159] 5.1 In order to prepare demulsification reagent, 10 ml of 6×SSC (Cat. No. 15557-036) and 200 μl of PFO (Cat. No. 370533-25G) were added to a 15 ml centrifuge tube.
[0160] 5.2 The filter device and the vacuum pump were connected, the pressure parameter was adjusted to 0.01 MPa or 100 mbar, and the vacuum pump was turned on.
[0161] 5.3 20 ml of 6×SSC was added to pretreat the device.
[0162] 5.4 When no liquid remained on the filter membrane, all the liquids in the collection tube were evenly poured on the surface of the filter membrane, the collection tube was washed twice with 2 ml of 6×SSC, and the cleaning solutions were together poured into the filter device.
[0163] 5.5 10 ml of demulsification reagent was vigorously inverted and mixed and then poured into the filter device quickly.
[0164] 5.6 When no liquid remained on the filter membrane, 30 ml of 6×SSC was continuously added to wash the magnetic beads.
[0165] 5.7 When no liquid remained on the filter membrane, the vacuum pump was turned off and the vacuum pump from the filter device were disconnected.
[0166] 5.8 The filter port of the filter device was closed with a syringe or rubber stopper.
[0167] 5.9 1.0 ml of collection buffer was added with a pipette, and the entire surface of the filter membrane was subjected to about 20 times of gentle pipetting to suspend the magnetic beads.
[0168] 5.10 The collection solution containing the magnetic beads was transferred to a 1.5 ml low adsorption centrifuge tube.
[0169] 5.11 1.0 ml of collection buffer was added with a pipette, and the entire surface of the filter membrane was subjected about 10 times of gentle pipetting to suspend the remaining magnetic beads.
[0170] 5.12 The collection solution containing magnetic beads was transferred to a 1.5 ml low-adsorption centrifuge tube, and the tube was placed on a magnetic stand and stood still for 2 min, and the supernatant was slowly removed.
[0171] 5.13 The centrifuge tube was removed from the magnetic stand. 100 μl of collection buffer was used to suspend the magnetic beads adsorbed on one side of the two centrifuge tubes in turn, and the liquid was transferred to 0.2 ml low adsorption PCR tube.
[0172] 5.14 100 μl of collection buffer was used to suspend the magnetic beads adsorbed on one side of the two centrifuge tubes again, and the liquid was transferred to the above-mentioned 0.2 ml low adsorption PCR tube.
[0173] 5.15 The PCR tube with magnetic beads was placed on the magnetic stand and stood still for 2 min, and then the supernatant was removed.
[0174] 5.16 The magnetic beads were kept in the adsorbed state, 200 μl of 6×SSC was added and stood still for 30 s, and then the supernatant was removed.
[0175] 5.17 200 μl of 5×FS Buffer was added and stood still for 30 s, and the supernatant was slowly removed to avoid attracting magnetic beads.
[0176] 6. Reverse Transcription Reaction
[0177] 6.1 Reverse transcription reaction system was prepared on ice: 5 μl of H.sub.2O, 20 μl of 5× First-Strand Buffer (Cat. No.: 01E022MS), 20 μl of 5M Betaine (Cat. No.: B0300-1VL), 10 μl of 10 mM dNTPs (Cat. No.: N0447L), 7.5 μl of 100 mM MgCl.sub.2 (Cat. No. 20-303), 5 μl of 50 μM Template switch oligo, 5 μl of 100 mM DTT (Cat. No. 01E022MS), 5 μl of 200 U/μl Alpha reverse transcriptase (Cat. No. 01E022MS), and 2.5 μl of 40 U/μl RNase inhibitor (Cat. No. 01E019MS).
[0178] The above-mentioned Alpha reverse transcriptase is an engineered MMLV reverse transcriptase, which can recognize ssDNA as a template for complementary synthesis.
[0179] 6.2 100 μl of the reverse transcription reaction system was pipetted and added to the PCR tube containing magnetic beads, and mixed by repeatedly pipetting.
[0180] 6.3 Reverse transcription reaction was performed according to the following conditions: 42° C., 90 min; and 10 cycles (50° C., 2 min; 42° C., 2 min), with thermal cover at 75° C. Due to the sedimentation of the magnetic beads, the magnetic beads were evenly mixed through gentle pipetting every 20 min, and the reaction continued after a brief centrifugation.
[0181] 6.4 After completion of the reaction, the tube was centrifuged briefly, placed on the magnetic stand, stood still for 2 min, and the reaction solution was removed.
[0182] 6.5 The PCR tube was removed from the magnetic stand, 200 μl of TE-SDS was added and shaken to evenly mix, and the reaction was terminated.
[0183] 6.6 After a brief centrifugation, the tube was placed on the magnetic stand, stood still for 2 min, and then the liquid was removed.
[0184] 6.7 The magnetic beads were kept in the adsorbed state, 200 μl of TE-TW was added, and the mixture stood still for 30 s, and then the supernatant was removed.
[0185] 6.8 The previous step repeated.
[0186] 6.9 The magnetic beads were kept in the adsorbed state, 200 μl of 10 mM Tris (pH8.0) was added, and the mixture stood still for 30 s, and then the supernatant was removed.
[0187] 7. Digestion of Empty Oligos Failing to Capture mRNA Molecules on Surfaces of Microbeads
[0188] 7.1 Digestion reaction system: 170 μl of H.sub.2O, 20μl of 10×EXO I Buffer, and 10p of EXO I enzyme.
[0189] 7.2 200 μl of the digestion reaction system was pipetted and added to the PCR tube containing magnetic beads, and evenly mixed by vortex.
[0190] 7.3 After brief centrifugation, the tube was placed in a PCR amplifier, and incubated at 37° C. for 45 min, with thermal cover at 75° C. The magnetic beads were evenly mixed through gentle pipetting every 15 min, and the reaction continued after brief centrifugation.
[0191] 7.4 After completion of the reaction, the tube was centrifuged briefly, placed on the magnetic stand, stood still for 2 min, and the reaction solution was removed.
[0192] 7.5 The PCR tube was removed from the magnetic stand, 200 μl of TE-SDS was added and shaken to evenly mix, and the reaction was terminated
[0193] 7.6 After brief centrifugation, the tube was placed on a magnetic stand, stood still for 2 min, and then the liquid was removed.
[0194] 7.7 The magnetic beads were kept in the adsorbed state, 200 μl of TE-TW was added, and the mixture stood still for 30 s, and then the supernatant was removed.
[0195] 7.8 The PCR tube was removed from the magnetic stand, 200 μl of TE-TW was added to suspend the magnetic beads.
[0196] 7.9 After brief centrifugation, the tube was placed on the magnetic stand, stood still for 2 min, and then the liquid was removed.
[0197] 7.10 The magnetic beads were kept in the adsorbed state, 200 μl of H.sub.2O was added, and the mixture stood still for 30 s, and then the supernatant was removed.
[0198] 8. cDNA Amplification
[0199] 8.1 A PCR reaction system was prepared: 41 μl of H.sub.2O, 8 μl of 10 μM Tn Primer, 2 μl of 1 μM reverse primer, 50 μl of 2×KAPA HiFi Hotstart Ready mix (Cat. No.: KK2602).
[0200] 8.2 PCR reaction was performed according to the following conditions: 95° C., 3 min; 13 to 20 cycles (98° C., 20 s; 58° C., 20 s; 72° C., 3 min).
[0201] 8.3 After the completion of PCR, the PCR product was purified and recovered by using 60 μl of (0.6×) AMPure XP Beads (Cat. No.: A63881) (pre-equilibrated at room temperature for 30 minutes), the oligo small fragment product was recovered in the supernatant by using 200 μl of (2×) AMPure XP beads, and the concentration was detected by using Qubit dsDNA HS Kit (Cat. No. Q32854).
[0202] 8.4 A DNB-Oligo purified product secondary amplification PCR reaction system was prepared: 141 μl of H.sub.2O, 2 μl of 10 μM V4-Phos-Tn-C Primer, 2 μl of 10 μM V2-N7-index-n Primer, 25 μl of 2×KAPA HiFi Hotstart Ready mix, and 10 μl of DNB-Oligo purified product obtained in step 8.3.
[0203] 8.5 PCR reaction was performed according to the following conditions: 95° C., 3 min; 6 to 10 cycles (98° C., 20 s; 58° C., 20 s; 72° C., 15 s).
[0204] 8.6 The oligo secondary amplification product was recovered by using 200 μl of (2×) AMPure XP beads, and the concentration was detected using the Qubit dsDNA HS Kit.
[0205] 9. Fragmentase Library Construction
[0206] 9.1 The fragmentase was taken and evenly mixed by shaking for 5 s, and the tube was centrifuged briefly and placed on ice for later use.
[0207] 9.2 50 to 300 ng of cDNAs to be interrupted was added into a new 0.2 ml PCR tube, a volume thereof ≤16 μl, and added with H.sub.2O to 16 μl.
[0208] 9.3 4.0 μl of the prepared fragmentation reaction solution (2 μl fragmentase (Cat. No.: M0348L) and 2 μl of 10× fragmentase buffer (Cat. No.: B0349) were pipetted and added into the cDNA tube, and mixed by vortex for 3 times, 3 s each time, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0209] 9.4 The PCR tube was placed on the PCR amplifier and incubated at 37° C. for 10 min.
[0210] 9.5 30 μl of 0.1M EDTA was added to the PCR tube, evenly mixed by vortex, and the reaction was terminated.
[0211] 9.6 The reaction solution was collected to the bottom of the tube through a brief centrifugation, and placed on ice.
[0212] 9.7 Fragment selection was performed on the fragmentation product by using 0.6×+0.4× (i.e., 30 μl+20 μl) AMPure XP beads, and the DNAs were eluted with 42 μl of H.sub.2O.
[0213] 9.8 End repair reaction solution was prepared on ice: 2.3 μl of H.sub.2O, 5 μl of 10×PNK buffer (Cat. No. B9040L), 1.2 μl of 5:1 dATP: dNTP mix, 0.6 μl of 10 U/μl T4 Polynucleotide Kinase (Cat. No. Y9040L), 0.6 μl of 3 U/μl T4 DNA polymerase (Cat. No. P7080L), 0.2 μl of 5 U/μl rTaq (Cat. No. R500Z), and 0.1 μl of 5 U/μl Klenow fragment (Cat. No. P7060L).
[0214] 9.9 10 μl of the end repair reaction solution was pipetted and added into the selected fragmentation product, evenly mixed by vortex, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0215] 9.10 The PCR tube was incubated on the PCR amplifier at 37° C. for 30 min, and at 65° C. for 15 min.
[0216] 9.11 After completion of the reaction, the reaction solution was placed on ice.
[0217] 9.12 An adapter ligation reaction solution was prepared on ice: 3.6 μl of H.sub.2O, 3 μl of 10×PNK buffer, 5 μl of 10 μM Adapters mix, 0.8 μl of 100 mM ATP (Cat. No. R1441), 16 μl of 50% PEG 8000 (Cat. No. EB-0.5P8K-250), and 1.6 μl of 600 U/μl T4 DNA Ligase (Cat. No. BGE004).
[0218] 9.13 30 μl of the prepared adapter ligation reaction solution was slowly pipetted and added to the end repair product, evenly mixed by vortex, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0219] 9.14 The PCR tube was placed on the PCR amplifier and incubated at 23° C. for 60 min.
[0220] 9.15 After completion of the reaction, 20 μl of TE Buffer was added to make the total sample volume to reach 100p.
[0221] 9.16 The ligation product was purified and recovered by using 50p of AMPure XP Beads, and the ligation product was eluted by using 48 μl of H.sub.2O.
[0222] 9.17 2 μl of 10 μM PCR Primer and 50 μl of 2×KAPA HiFi Hotstart Ready mix were added and evenly mixed by shaking.
[0223] 9.18 PCR reaction was performed according to the following conditions: 95° C., 3 min; 11 cycles (98° C., 20 s; 58° C., 20 s; 72° C., 30 s).
[0224] 9.19 After completion of PCR, the PCR product was screened by using 0.6x+0.2× (i.e., 60 μl+20 μl) AMPure XP Beads, DNAs were eluted using 42 μl of TE Buffer, and the concentration was detected using Qubit dsDNA HS Kit.
[0225] 10. High-Throughput Sequencing
[0226] 10.1 A total of 200 to 400 ng of the library was added into a new 0.2 ml PCR tube, where a pooling ratio of the PCR product of cDNAs of the same sample after fragmentation and the oligo secondary PCR product was 9:1 (or, separate cyclization and then pooling). TE Buffer was added to reach a total volume of 47 μl.
[0227] 10.2 3.0 μl of 20 μM Splint Oligo primer was added and evenly mixed, and centrifuged briefly to precipitate to the bottom of the tube.
[0228] 10.3 The tube was placed in a PCR amplifier and incubated at 95° C. for 3 min.
[0229] 10.4 Immediately after completion of the reaction, the PCR tube was transferred onto ice and stood still for 5 min.
[0230] 10.5 A single strand cyclization reaction solution was prepared on ice: 3.241 of TE Buffer, 6 μl of 10× TA buffer, 0.6 μl of 100 mM ATP, and 0.241 of 600 U/μl T4 DNA Ligase.
[0231] 10.6 10 μl of the prepared single strand cyclization reaction solution was pipetted and added into the above PCR tube, evenly mixed by vortex, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0232] 10.7 The PCR tube was placed on the PCR amplifier and incubated at 37° C. for 30 min.
[0233] 10.8 The digestion reaction solution was prepared on ice: 1.0 μl of TE Buffer, 0.4 μl of 10×TA buffer, 1.95 μl of 20 U/μl EXO I, and 0.65 μl of 100 U/μl EXO III.
[0234] 10.9 4 μl of the digestion reaction solution was pipetted and added to the single strand cyclization product, evenly mixed by vortex, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0235] 10.10 The tube was placed on the PCR amplifier and incubated at 37° C. for 30 min.
[0236] 10.11 After completion of the reaction, 3 μl of 0.5M EDTA was added and mixed, and the mixture was centrifuged.
[0237] 10.12 The above digestion product was recovered by using 90 μl of PEG32 magnetic beads, DNAs were eluted with 3241 of TE Buffer, and the concentration of single-stranded cyclic library was detected by using the Qubit® ssDNAAssay Kit.
[0238] 10.13 The qualified library was sequenced. The sequencing parameters: 41+100+10.
[0239] The experimental product and library quality inspection result are as follows:
[0240]
[0241] After sequencing analysis, the results are shown in Table 1 below and
TABLE-US-00003 TABLE 1 Transcriptome sequencing results Estimated number of cells 1689 Reads in cell 0.421 Mean UMI counts per cell 11710 Mean genes per cell 3441
[0242] Table 1 and
[0243]
[0244]
[0245]
Example 2
[0246] Example 2 provides a method for preparing a sequencing library and performing high-throughput sequencing. The provided method is implemented through several steps, including: barcode vector microbead preparation, single cell suspension preparation, microbead preparation, droplet generation, demulsification, reverse transcription RT reaction, enzyme digestion, cDNA amplification, fragmentase library construction, high-throughput sequencing, etc.
[0247] 1. Preparation of Microbead Vectors Carrying Droplet Index Sequences
[0248] 1.1 Coupling incubation of microbead vector oligonucleotides carrying droplet index sequences:
[0249] For each group, 200 pmol of modified droplet index sequence oligonucleotides were taken and incubated with 1 mg of Dynabeads™ M-280 Streptavidin magnetic beads at room temperature for 2 hours. After incubation, the magnetic beads were attracted to the magnetic stand and washed 3 times, and the magnetic beads were stored in low salt buffer. Buffer for incubation and washing of magnetic beads: (B&W) Buffer (1×) (5 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 1M NaCl).
[0250] The used droplet index sequence oligonucleotides:
TABLE-US-00004 5’-/Biotin/Disulfide/TTGTCTTCCTAAGACCGCTTG GCCTCCGACTT [Tag2]
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-3′
[0251] The sequence denoted with single line represents a PCR adapter sequence, and the following 10 bases represent the droplet index sequence. A total of 12 types were used in this example, and the following sequence denoted with a wavy line represents random bases for optimizing a sequencing quality of the barcode region. The base B immediately following the random bases is a degenerate base, which may be G, C or T. The sequence denoted with double lines represents a polyA sequence, which is used to be captured by an oligonucleotide on another magnetic bead (i.e., the magnetic bead carrying the cell index sequence) in the droplet. The 5′-end of this oligonucleotide strand has Biotin medication and disulfide bond modification.
[0252] 1.2 Mixing and Counting of Droplet Barcode Vector Microbeads
[0253] After 12 groups of barcode vector microbeads were prepared through incubation according to the above step, each group was mixed with an equal amount of magnetic beads, and the mixed barcode vector microbeads were counted for the last time to obtain the microbead concentration.
[0254] 2. Preparation of Single Cell Suspension
[0255] 2.1 Single cell suspension for 293T cell line was prepared by trypsin digestion, washed with PBS (Cat. No.: 10010031) (containing 0.04% BSA) 1-2 times, and filtrated with 40 μm cell sieve.
[0256] 2.2 The cell concentration was detected with a cell counting plate or counter.
[0257] 2.3 Based on the cell concentration, 20,000 cells were taken through pipette each time, and the cell pellet was collected after centrifugation at 300-500 g, and 100 μl of Cell Resuspension Buffer was added to resuspend the cells.
[0258] 2.4 2.2 million mixed barcode vector microbeads obtained in the above step 1.2 were added to the Cell Resuspension Buffer before sample loading. The specific volume was determined according to the concentration. The mixture was placed on ice for sample loading.
[0259] 3. Microbead Preparation
[0260] 3.1 With reference to the literature published by BGI about a stLFR magnetic bead preparation method (Efficient and unique co-barcoding of second-generation sequencing reads from long DNA molecules enabling cost effective and accurate sequencing, haplotyping, and de novo assembly, https://genome.cshlp.org/content/early/2019/04/02/gr.245126.118), magnetic beads (purchased from Spherotech, USA, Cat. No.: SVM-200-4, https://www.spherotech.com/coa_mag_par.htm) were subjected to surface oligonucleotide coating to obtain magnetic beads with oligonucleotides on the surfaces thereof 200 μl of magnetic beads (220,000) were pipetted and added to into 0.2 ml PCR tube, placed on a magnetic stand for 2 min, and then the supernatant was removed.
[0261] 3.2 The PCR tube was removed from the magnetic stand, and added with 200 μl of 1× Buffer D (1 mM EDTA, 9 mg/ml 85% KOH) to suspend the magnetic beads.
[0262] 3.3 The tube was incubated at room temperature for 5 min.
[0263] 3.4 The tube was placed on the magnetic stand for 2 min, and then the supernatant was removed.
[0264] 3.5 The PCR tube was kept on the magnetic stand, added with 200 μl of 1× Buffer D, and stood still for 30 s to remove the supernatant.
[0265] 3.6 200 μl of LSWB was added and stood for 30 s, and then the supernatant was removed.
[0266] 3.7 The previous step repeated.
[0267] 3.8 200 μl of Lysis Buffer (6% Ficoll PM-400 (Cat. No.: 17-0300-10), 0.2% Sarkosyl (Cat. No.: L7414), 20 mM EDTA, 200 mM Tris pH 7.5 (Cat. No.: T2944-1L), H.sub.2O) was added and stood for 30 s, and then the supernatant was removed. The PCR tube was removed from the magnetic stand, added with 99 μl of Lysis Buffer and 11 μl of 1M DTT to obtain a final concentration of 100 mM DTT in this buffer. The magnetic beads were suspended with a low adsorption pipette tip on ice.
[0268] 4. Droplet Generation
[0269] 4.1 A protective film on a surface of a chip was teared off, and the chip was placed in a chip slot region of a droplet generator. The chip has a structure as illustrated in
[0270] 4.2 An A-end of a connection tube on a collection cap (contacting the connection tube at the bottom of the collection tube) was placed into an outlet hole of the chip.
[0271] 4.3 A 50 ml syringe was placed on a fixing holder and the push rod was pushed to an initial position. A blunt-end syringe needle was used to connect the syringe with the B-end of the connecting tube on the cap of the collection tube (without contacting the connecting tube at the bottom of the collection tube).
[0272] 4.4 200 μl of droplet generation oil was added to the collection tube, the collection cap was tightened, and the collection tube was placed upright on the fixing holder.
[0273] 4.5 The cells were evenly mixed through gentle pipetting, and 100 μl of the single cell suspension (obtained in step 2 above) was added to the cell well of the chip, under the premise that the pipette tip touched the bottom of the well.
[0274] 4.6 The magnetic beads were evenly mixed through gentle pipetting, and 100 μl of magnetic beads (obtained in step 3 above) were added to the bead well of the chip, under the premise that the pipette tip touched the bottom of the well.
[0275] 4.7 350 μl of the droplet generation oil was immediately added to the oil well of the chip.
[0276] 4.8 The push rod of the syringe was quickly pulled to the slot position, and the push rod was clamped at the slot.
[0277] 4.9 A timer was activated for 8 min and the droplets were collected.
[0278] 4.10 After 8 minutes, the collection cap on the collection tube was immediately unscrewed. The connection tube of the outlet hole of the chip was pulled out, and the connection tube was stretched vertically. The droplets in the tube flow into the collection tube, and then an ordinary collection tube cap was used for replacement.
[0279] 4.11 The collection tube stood still at room temperature for 20 min to fully bind mRNA molecules to the magnetic beads.
[0280] 5. Demulsification
[0281] 5.1 In order to prepare demulsification reagent, 10 ml of 6×SSC (Cat. No. 15557-036) and 200 μl of PFO (Cat. No. 370533-25G) were added to a 15 ml centrifuge tube.
[0282] 5.2 The filter device and the vacuum pump were connected, the pressure parameter was adjusted to 0.01 Mpa or 100 mbar, and the vacuum pump was turned on.
[0283] 5.3 20 ml of 6×SSC was added to pretreat the device.
[0284] 5.4 When no liquid remained on the filter membrane, all the liquids in the collection tube were evenly poured on the surface of the filter membrane, the collection tube was washed twice with 2 ml of 6×SSC, and the cleaning solutions were together poured into the filter device.
[0285] 5.5 10 ml of demulsification reagent was vigorously inverted and mixed and then poured into the filter device quickly.
[0286] 5.6 When no liquid remained on the filter membrane, 30 ml of 6×SSC was continuously added to wash the magnetic beads.
[0287] 5.7 When no liquid remained on the filter membrane, the vacuum pump was turned off and the vacuum pump from the filter device were disconnected.
[0288] 5.8 The filter port of the filter device was closed with a syringe or rubber stopper.
[0289] 5.9 1.0 ml of collection buffer was added with a pipette, and the entire surface of the filter membrane was subjected to about 20 times of gentle pipetting to suspend the magnetic beads.
[0290] 5.10 The collection solution containing the magnetic beads was transferred to a 1.5 ml low adsorption centrifuge tube.
[0291] 5.11 1.0 ml of collection buffer was added with a pipette, and the entire surface of the filter membrane was subjected about 10 times of gentle pipetting to suspend the remaining magnetic beads.
[0292] 5.12 The collection solution containing magnetic beads was transferred to a 1.5 ml low-adsorption centrifuge tube, and the tube was placed on a magnetic stand and stood still for 2 min, and the supernatant was slowly removed.
[0293] 5.13 The centrifuge tube was removed from the magnetic stand. 100 μl of collection buffer was used to suspend the magnetic beads adsorbed on one side of the two centrifuge tubes in turn, and the liquid was transferred to 0.2 ml low adsorption PCR tube.
[0294] 5.14 100 μl of collection buffer was used to suspend the magnetic beads adsorbed on one side of the two centrifuge tubes again, and the liquid was transferred to the above-mentioned 0.2 ml low adsorption PCR tube.
[0295] 5.15 The PCR tube with magnetic beads was placed on the magnetic stand and stood still for 2 min, and then the supernatant was removed.
[0296] 5.16 The magnetic beads were kept in the adsorbed state, 200 μl of 6×SSC was added and stood still for 30 s, and then the supernatant was removed.
[0297] 5.17 200 μl of 5×FS Buffer was added and stood still for 30 s, and the supernatant was slowly removed to avoid attracting magnetic beads.
[0298] 6. Reverse Transcription Reaction
[0299] 6.1 Reverse transcription reaction system was prepared on ice: 5 μl of H.sub.2O, 20 μl of 5× First-Strand Buffer (Cat. No.: 01E022MS), 20 μl of 5M Betaine (Cat. No.: B0300-1VL), 10 μl of 10 mM dNTPs (Cat. No.: N0447L), 7.5 μl of 100 mM MgCl.sub.2 (Cat. No. 20-303), 5 μl of 50 μM Template switch oligo, 5 μl of 100 mM DTT (Cat. No. 01E022MS), 5 μl of 200 U/μl Alpha reverse transcriptase (Cat. No. 01E022MS), and 2.5 μl of 40 U/μl RNase inhibitor (Cat. No. 01E019MS).
[0300] The above-mentioned Alpha reverse transcriptase is an engineered MMLV reverse transcriptase, which can recognize ssDNA as a template for complementary synthesis.
[0301] 6.2 100 μl of the reverse transcription reaction system was pipetted and added to the PCR tube containing magnetic beads, and mixed by repeatedly pipetting.
[0302] 6.3 Reverse transcription reaction was performed according to the following conditions: 42° C., 90 min; and 10 cycles (50° C., 2 min; 42° C., 2 min), with thermal cover at 75° C. Due to the sedimentation of the magnetic beads, the magnetic beads were evenly mixed through gentle pipetting every 20 min, and the reaction continued after a brief centrifugation.
[0303] 6.4 After completion of the reaction, the tube was centrifuged briefly, placed on the magnetic stand, stood still for 2 min, and the reaction solution was removed.
[0304] 6.5 The PCR tube was removed from the magnetic stand, 200 μl of TE-SDS was added and shaken to evenly mix, and the reaction was terminated.
[0305] 6.6 After a brief centrifugation, the tube was placed on the magnetic stand, stood still for 2 min, and then the liquid was removed.
[0306] 6.7 The magnetic beads were kept in the adsorbed state, 200 μl of TE-TW was added, and the mixture stood still for 30 s, and then the supernatant was removed.
[0307] 6.8 The previous step repeated.
[0308] 6.9 The magnetic beads were kept in the adsorbed state, 200 μl of 10 mM Tris (pH8.0) was added, and the mixture stood still for 30 s, and then the supernatant was removed.
[0309] 7. Digestion of Empty Oligos Failing to Capture mRNA Molecules on Surfaces of Microbeads
[0310] 7.1 Digestion reaction system: 170 μl of H.sub.2O, 20 μl of 10×EXO I Buffer, and 10 μl of EXO I enzyme.
[0311] 7.2 200 μl of the digestion reaction system was pipetted and added to the PCR tube containing magnetic beads, and evenly mixed by vortex.
[0312] 7.3 After brief centrifugation, the tube was placed in a PCR amplifier, and incubated at 37° C. for 45 min, with thermal cover at 75° C. The magnetic beads were evenly mixed through gentle pipetting every 15 min, and the reaction continued after brief centrifugation.
[0313] 7.4 After completion of the reaction, the tube was centrifuged briefly, placed on the magnetic stand, stood still for 2 min, and the reaction solution was removed.
[0314] 7.5 The PCR tube was removed from the magnetic stand, 200 μl of TE-SDS was added and shaken to evenly mix, and the reaction was terminated
[0315] 7.6 After brief centrifugation, the tube was placed on a magnetic stand, stood still for 2 min, and then the liquid was removed.
[0316] 7.7 The magnetic beads were kept in the adsorbed state, 200 μl of TE-TW was added, and the mixture stood still for 30 s, and then the supernatant was removed.
[0317] 7.8 The PCR tube was removed from the magnetic stand, 200 μl of TE-TW was added to suspend the magnetic beads.
[0318] 7.9 After brief centrifugation, the tube was placed on the magnetic stand, stood still for 2 min, and then the liquid was removed.
[0319] 7.10 The magnetic beads were kept in the adsorbed state, 200 μl of H.sub.2O was added, and the mixture stood still for 30 s, and then the supernatant was removed.
[0320] 8. cDNA Amplification
[0321] 8.1 A PCR reaction system was prepared: 46 μl of H.sub.2O, 4 μl of 10 μM Tn Primer, and 50 μl of 2×KAPA HiFi Hotstart Ready mix (Cat. No.: KK2602).
[0322] 8.2 PCR reaction was performed according to the following conditions: 95° C., 3 min; 13 to 20 cycles (98° C., 20 s; 58° C., 20 s; 72° C., 3 min).
[0323] 8.3 After the completion of PCR, the PCR product was purified and recovered by using 60 μl of (0.6×) AMPure XP Beads (Cat. No.: A63881) (pre-equilibrated at room temperature for 30 minutes), the oligo small fragment product was recovered in the supernatant by using 200 μl of (2×) AMPure XP beads, and the concentration was detected by using Qubit dsDNA HS Kit (Cat. No. Q32854).
[0324] 8.4 A droplet molecular barcode purification product secondary amplification PCR reaction system was prepared: 11 μl of H.sub.2O, 2μl of 10 μM V4-Phos-Tn-C Primer, 2 μl of 10 μM V2-N7-index-n Primer, 25 μl of 2×KAPA HiFi Hotstart Ready mix, and 10 μl of oligo small fragment purification product of step 8.3.
[0325] 8.5 PCR reaction was performed according to the following conditions: 95° C., 3 min; 6 to 10 cycles (98° C., 20 s; 58° C., 20 s; 72° C., 15 s).
[0326] 8.6 The oligo secondary amplification product was recovered by using 200 μl of (2×) AMPure XP Microbeads, and the concentration was detected using the Qubit dsDNA HS Kit.
[0327] 9. Fragmentase Library Construction
[0328] 9.1 The cDNA product was subjected to the following library construction procedures: taking out the fragmentase, shaking and mixing for 5 s, centrifuging briefly, and placing on ice for later use.
[0329] 9.2 50 to 300 ng of cDNAs to be interrupted was added into a new 0.2 ml PCR tube, a volume thereof ≤16 μl, and added with H.sub.2O to 16 μl.
[0330] 9.3 4.0 μl of the prepared fragmentation reaction solution (2 μl fragmentase (Cat. No.: M0348L) and 2 μl of 10× fragmentase buffer (Cat. No.: B0349) were pipetted and added into the cDNA tube, and mixed by vortex for 3 times, 3 s each time, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0331] 9.4 The PCR tube was placed on the PCR amplifier and incubated at 37° C. for 10 min.
[0332] 9.5 30 μl of 0.1M EDTA was added to the PCR tube, evenly mixed by vortex, and the reaction was terminated.
[0333] 9.6 The reaction solution was collected to the bottom of the tube through a brief centrifugation, and placed on ice.
[0334] 9.7 Fragment selection was performed on the fragmentation product by using 0.6×+0.4× (i.e., 30 μl+20 μl) AMPure XP beads, and the DNAs were eluted with 42 μl of H.sub.2O.
[0335] 9.8 End repair reaction solution was prepared on ice: 2.3 μl of H.sub.2O, 5 μl of 10×PNK buffer (Cat. No. B9040L), 1.2 μl of 5:1 dATP: dNTP mix, 0.6 μl of 10 U/pI T4 Polynucleotide Kinase (Cat. No. Y9040L), 0.6 μl of 3 U/μl T4 DNA polymerase (Cat. No. P7080L), 0.2 μl of 5 U/μl rTaq (Cat. No. R500Z), and 0.1 μl of 5 U/μl Klenow fragment (Cat. No. P7060L).
[0336] 9.9 10 μl of the end repair reaction solution was pipetted and added to the selected fragmentation product, evenly mixed by vortex, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0337] 9.10 The PCR tube was incubated on the PCR amplifier at 37° C. for 30 min, and at 65° C. for 15 min.
[0338] 9.11 After completion of the reaction, the reaction solution was placed on ice.
[0339] 9.12 An adapter ligation reaction solution was prepared on ice: 3.6 μl of H.sub.2O, 3 μl of 10×PNK buffer, 5 μl of 10 μM Adapters mix, 0.8 μl of 100 mM ATP (Cat. No. R1441), 16 μl of 50% PEG 8000 (Cat. No. EB-0.5P8K-250), and 1.6 μl of 600 U/μl T4 DNA Ligase (Cat. No. BGE004).
[0340] 9.13 30 μl of the prepared adapter ligation reaction solution was slowly pipetted and added to the end repair product, evenly mixed by vortex, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0341] 9.14 The PCR tube was placed on the PCR amplifier and incubated at 23° C. for 60 min.
[0342] 9.15 After completion of the reaction, 20 μl of TE Buffer was added to make the total sample volume reach 100p.
[0343] 9.16 The ligation product was purified and recovered by using 50 μl of AMPure XP Beads, and the ligation product was eluted by using 48 μl of H.sub.2O.
[0344] 9.17 2 μl of 10 μM PCR Primer and 50 μl of 2×KAPA HiFi Hotstart Ready mix were added and evenly mixed by shaking.
[0345] 9.18 PCR reaction was performed according to the following conditions: 95° C., 3 min; 11 cycles (98° C., 20 s; 58° C., 20 s; 72° C., 30 s).
[0346] 9.19 After completion of PCR, the PCR product was screened by using 0.6x+0.2× (i.e., 60 μl+20 μl) AMPure XP Beads, DNAs were eluted using 42 μl of TE Buffer, and the concentration was detected using Qubit dsDNA HS Kit.
[0347] 10. High-Throughput Sequencing
[0348] 10.1 A total of 200 to 400 ng of the library was added into a new 0.2 ml PCR tube, where a pooling ratio of the PCR product of cDNAs of the same sample after fragmentation and the oligo secondary PCR product was 9:1 (or, separate cyclization and then pooling). TE Buffer was added to reach a total volume of 471.
[0349] 10.2 3.0 μl of 20 μM Splint Oligo primer was added and evenly mixed, and centrifuged briefly to precipitate to the bottom of the tube.
[0350] 10.3 The tube was placed in a PCR amplifier and incubated at 95° C. for 3 min.
[0351] 10.4 Immediately after completion of the reaction, the PCR tube was transferred onto ice and stood still for 5 min.
[0352] 10.5 A single strand cyclization reaction solution was prepared on ice: 3.2 μl of TE Buffer, 6 μl of 10×TA buffer, 0.6 μl of 100 mM ATP, and 0.2 μl of 600 U/μl T4 DNA Ligase.
[0353] 10.6 10 μl of the prepared single strand cyclization reaction solution was pipetted and added into the above PCR tube, evenly mixed by vortex, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0354] 10.7 The PCR tube was placed on the PCR amplifier and incubated at 37° C. for 30 min.
[0355] 10.8 The digestion reaction solution was prepared on ice: 1.0 μl of TE Buffer, 0.4 μl of 10×TA buffer, 1.95 μl of 20 U/μl EXO I, and 0.65 μl of 100 U/μl EXO III.
[0356] 10.9 4 μl of the digestion reaction solution was pipetted and added to the single strand cyclization product, evenly mixed by vortex, and centrifuged briefly to collect the reaction solution to the bottom of the tube.
[0357] 10.10 The tube was placed on the PCR amplifier and incubated at 37° C. for 30 min.
[0358] 10.11 After completion of the reaction, 3 μl of 0.5M EDTA was added and mixed, and the mixture was centrifuged.
[0359] 10.12 The above digestion product was recovered by using 90 μl of PEG32 magnetic beads, DNAs were eluted with 32 μl of TE Buffer, and the concentration of single-stranded cyclic library was detected by using the Qubit® ssDNAAssay Kit.
[0360] 10.13 The qualified library was sequenced. The sequencing parameters: 41+100+10.
[0361] The experimental product and library quality inspection result are as follows:
[0362]
[0363] After sequencing analysis, the results are shown in Table 2 below and
TABLE-US-00005 TABLE 2 Transcriptome sequencing results. Estimated number of cells 1055 Reads in cell 0.276 Mean UMI counts per cell 218 Mean genes per cell 140
[0364] Table 2 and
[0365]
[0366]
[0367]
[0368]
[0369]
[0370] In the specification, description with reference to the terms “an embodiment,” “some embodiments,” “example”, “specific example” or “some examples”, etc., mean that specific features, structures, materials, or characteristics described in connection with the embodiment or example is included in at least one embodiment or example of the present disclosure. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, those skilled in the art may combine the different embodiments or examples described in this specification, as well as the features of the different embodiments or examples, as long as they do not conflict each other.
[0371] Although the embodiments of the present disclosure have been illustrated and described above, it should be understood that the above-mentioned embodiments are exemplary and should not be construed as limiting the present disclosure. Those skilled in the art may make changes, modifications, replacements and variations to the above embodiments within the scope of the present disclosure.